Brought to you by 
Series B brings in $28.5mm for Intellikine
21 Dec 2011
Executive Summary
Intellikine (therapies for autoimmune diseases, cancer, and inflammation) raised $28.5mm through its second round of venture financing. Novartis Bioventures (which gets a seat on the company's board) led and was joined by new investors US Venture Partners, Biogen Idec, and FinTech Global Capital. Series A backers Abingworth, CMEA Capital, and Sofinnova Ventures also participated. The company could bring in an additional $22.5mm based on the achievement of certain milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $28.5mm for Intellikine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice